| Mohamed Hanaif, PHARMD | |
|
176 Hill St, Ansonia, CT 06401-2462 | |
| (203) 308-6744 | |
| Not Available |
| Full Name | Mohamed Hanaif |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 176 Hill St, Ansonia, Connecticut |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649938077 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PCT.0015313 (Connecticut) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mohamed Hanaif, PHARMD 176 Hill St, Ansonia, CT 06401-2462 Ph: (203) 308-6744 | Mohamed Hanaif, PHARMD 176 Hill St, Ansonia, CT 06401-2462 Ph: (203) 308-6744 |
News Archive
People with "prediabetes" (a high risk state for overt type 2 diabetes) who experience a period of normal glucose regulation are 56% less likely to develop diabetes 5∙7 years later, according to a new research Article presented at the American Diabetes Association 72nd Scientific Sessions on Saturday 9 June, and published Online First in The Lancet. This is one of four Articles (all presented at the American Diabetes Association 72nd Scientific Sessions) and a Series of three papers that are part of a special Lancet theme issue on diabetes [1].
A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results.
The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.
In a Canadian first, a medical team has implanted a wireless device inside a heart failure patient, permitting clinicians to monitor the patient's cardiovascular status – virtually and in real-time – and proactively adjust treatment to prevent costly, potentially unnecessary hospitalization.
› Verified 4 days ago
Anna Kucharczyk, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr, Ansonia, CT 06401 Phone: 203-735-7837 | |
Julia Marie Paterson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr # 36, Ansonia, CT 06401 Phone: 203-735-7837 | |
Melissa Bonanno, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr, Ansonia, CT 06401 Phone: 203-735-7837 | |
Michael G Deotte, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr, Ansonia, CT 06401 Phone: 203-735-7837 | |
Paul I Odiwo, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 404 Main St, Ansonia, CT 06401 Phone: 203-734-3152 | |
Mohamed Khatib, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr, Ansonia, CT 06401 Phone: 203-735-7837 | |
Dr. Jamie Durkin, PHARM-D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 24 Pershing Dr, Ansonia, CT 06401 Phone: 203-735-7837 Fax: 203-735-3080 |